SAB Biotherapeutics Confirms Nasdaq Listing, Warrant Details

Ticker: SABSW · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1833214

Sab Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySab Biotherapeutics, Inc. (SABSW)
Form Type8-K
Filed DateJan 19, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $11.50
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, stock-listing, warrants

TL;DR

**SABS confirms Nasdaq listing and $11.50 warrant exercise price.**

AI Summary

SAB Biotherapeutics, Inc. filed an 8-K on January 19, 2024, to disclose that its common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Stock Market under the trading symbol SABS. The filing also notes that warrants are exercisable for one share of common stock at an exercise price of $11.50 per share. This matters to investors because it confirms the company's listing on a major exchange and provides details on its warrant structure, which can impact share dilution and future capital raises.

Why It Matters

This filing confirms SAB Biotherapeutics' listing on The Nasdaq Stock Market and provides key details about its warrants, which is crucial for understanding the company's capital structure and potential future dilution for shareholders.

Risk Assessment

Risk Level: low — This filing is primarily informational, confirming existing details about the company's stock and warrants, and does not introduce new significant risks.

Analyst Insight

Investors should note the warrant exercise price of $11.50, as this could indicate a potential dilution event if warrants are exercised, or a price target for warrant holders. This filing primarily serves as a confirmation of existing information.

Key Numbers

  • $0.0001 — Common Stock Par Value (The stated par value per share of SAB Biotherapeutics' common stock.)
  • $11.50 — Warrant Exercise Price (The price at which each warrant can be exercised for one share of common stock.)

Key Players & Entities

  • SAB Biotherapeutics, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market (company) — the exchange where SABS common stock is registered
  • SABS (company) — the trading symbol for SAB Biotherapeutics, Inc. common stock
  • $0.0001 (dollar_amount) — par value per share of common stock
  • $11.50 (dollar_amount) — exercise price per share for warrants

FAQ

What is the par value of SAB Biotherapeutics, Inc.'s common stock as stated in this filing?

The par value of SAB Biotherapeutics, Inc.'s common stock is $0.0001 per share, as indicated in the filing under 'Common stock, $0.0001 par value per share'.

On which stock exchange is SAB Biotherapeutics, Inc.'s common stock registered?

SAB Biotherapeutics, Inc.'s common stock is registered on The Nasdaq Stock Market, as stated under 'Name of each exchange on which registered'.

What is the trading symbol for SAB Biotherapeutics, Inc. common stock?

The trading symbol for SAB Biotherapeutics, Inc. common stock is SABS, as listed under 'Trading Symbol(s)'.

What is the exercise price for each warrant mentioned in the filing?

Each warrant is exercisable for one share of common stock at an exercise price of $11.50 per share, as detailed in the filing's 'sabs:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember' section.

What was the 'Date of earliest event reported' for this 8-K filing?

The 'Date of earliest event reported' for this 8-K filing was January 19, 2024, as stated at the beginning of the Form 8-K.

Filing Stats: 940 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-01-19 16:21:56

Key Financial Figures

  • $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
  • $11.50 — of Common Stock at an exercise price of $11.50 per share SABSW The Nasdaq Stock Ma

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. SAB Biotherapeutics, Inc. (the Company or SAB) is making available an updated corporate presentation (the “Presentation”) on the Investor Relations section of the Company’s website. A copy of the Presentation is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. The information contained in the Presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. Cautionary Note Regarding Forward-Looking Statements Certain statements made in this current report and the Release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Presentation 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: January 19, 2024 By: /s/ Eddie J. Sullivan Eddie J. Sullivan Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.